Status:
COMPLETED
Pharmacokinetic of Doripenem and Piperacillin/Tazobactam in More Than 120 kg Critically Ill Patients
Lead Sponsor:
University Hospital, Montpellier
Conditions:
Septic Shock
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Overweight patients are susceptible to develop acute complications when they are admitted in an Intensive Care Unit (ICU). Severe infection can be associated with cardiovascular failure ('shock") and ...
Detailed Description
N=52 patients divided in 4\*13 patients (13 per antibiotic and per group, overweight or non overweight). Overweight is defined by a weight over 120kg. Antibiotic chosen by the intensivist in charge o...
Eligibility Criteria
Inclusion
- General:
- Patients in severe sepsis or septic shock defined by Bone criteria (proved or very suspected infection with organ impairment and/or need of vasopressive agent to keep a mean arterial pressure more than 65mmHg)
- Patient requiring a treatment by study's antibiotics
- Informed consent signed
- Patient must be affiliated or beneficiary of a social medical insurance
- Participation of patient to the trial must be noted in the medical file
- Specific to overweight patients: Weight \> 120kg
- Specific to no overweight patients: Weight less than or equal to 120kg
Exclusion
- Pregnant women
- Under age patient minor
- Patient protected by law
- Known allergy to study's antibiotics
Key Trial Info
Start Date :
February 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2013
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01517815
Start Date
February 1 2012
End Date
June 1 2013
Last Update
November 29 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Saint Eloi Intensive Care Unit - Montpellier University Hospital
Montpellier, France, 34295